Floatz logo

RG 4733

Pituitary Tumor

National Cancer Institute (NCI)Small moleculePhase 1Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pituitary Tumor cohort.

Asset / SponsorPhaseRating
Cabergoline
RECORDATI GROUP
Phase 4BB
Pasireotide
RECORDATI GROUP
Phase 4BB
Dexasone
National Cancer Institute (NCI)
Phase 1CC
Serostim
Federico II University
UnknownD

Same molecule, other indications

RG 4733 is also rated in:

melanomaDormant
CCC
Indicative · Phase 2
51 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative · Phase 2
51 / 100
View asset →
brain neoplasmDormant
CCC
Indicative · Phase 2
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →